Stempoint Capital’s Avidity Biosciences RNAM Stock Holding History

Stempoint Capital’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-75,000	Closed	-$184K	–	65
2024 Q1	$184K	Buy	+75,000	New	+$1.18M	0.05%	51

Other funds holding RNAM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stempoint Capital's RNAM Position: Q4 2025 in Review

Stempoint Capital sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 114,053 shares — an estimated $4.97M sold.

Stempoint Capital first reported a position in RNAM in Q3 2025 and held it in 1 quarter. The position peaked at $4.97M in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

Stempoint Capital reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
Stempoint Capital sold 114,053 Avidity Biosciences shares in Q4 2025, an estimated $4.97M.
Stempoint Capital first reported a position in Avidity Biosciences in Q3 2025 and held it in 1 quarter.
Stempoint Capital's Avidity Biosciences position peaked at $4.97M in Q3 2025.
343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Stempoint Capital's 13F filing for Q4 2025, filed 17 Feb 2026.